S. Bellone

发表

Improved i.p. drug delivery with bioadhesive nanoparticles

W. Saltzman, Junwei Zhang, E. Song, 2016, Proceedings of the National Academy of Sciences.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2016, Molecular Cancer Therapeutics.

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Gynecologic oncology.

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Molecular oncology.

The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells.

T. O'brien, S. Anfossi, L. E. De Las Casas, 2004, Gynecologic oncology.

The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer.

T. O'brien, L. E. De Las Casas, S. Bellone, 2004, American journal of obstetrics and gynecology.

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

Gloria S. Huang, E. Ratner, R. Angioli, 2020, Oncotarget.

High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

P. Schwartz, T. Rutherford, P. Todeschini, 2011, Gynecologic oncology.

Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti–Trop-2 Monoclonal Antibody

P. Schwartz, T. Rutherford, S. Lonardi, 2011, International Journal of Gynecologic Cancer.

Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

E. Ratner, D. Silasi, P. Schwartz, 2011, American journal of obstetrics and gynecology.

Overexpression of Clostridium perfringens Enterotoxin Receptors Claudin-3 and Claudin-4 in Uterine Carcinosarcomas

J. McKenney, E. Siegel, S. Bellone, 2007, Clinical Cancer Research.

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Gloria S. Huang, E. Ratner, Serena Wong, 2017, Gynecologic oncology.

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.

E. Siegel, S. Bellone, A. Santin, 2005, American journal of obstetrics and gynecology.

Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer

E. Diamandis, S. Bellone, A. Santin, 2005, Clinical Cancer Research.

In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells.

S. Bellone, A. Santin, M. Cannon, 2003, The Journal of surgical research.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

S. Canevari, P. Schwartz, T. Rutherford, 2014, Clinical & Experimental Metastasis.

Current treatment options for endometrial cancer

T. O'brien, S. Bellone, A. Santin, 2004, Expert review of anticancer therapy.

Effect of blood transfusion during radiotherapy on the immune function of patients with cancer of the uterine cervix: role of interleukin-10.

G. Parham, S. Bellone, A. Santin, 2002, International journal of radiation oncology, biology, physics.

Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix.

G. Parham, P. Hermonat, S. Bellone, 2000, International journal of radiation oncology, biology, physics.

Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation.

D. DiMaio, S. Bellone, A. Santin, 2012, Virology.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Gloria S. Huang, Abhijit A. Patel, D. Levine, 2018, Gynecologic oncology.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Scientific Reports.

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor

D. Silasi, P. Schwartz, T. Rutherford, 2011, BMC Cancer.

Induction of tumour-specific CD8+ cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer

G. Parham, S. Bellone, A. Santin, 2002, British Journal of Cancer.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.

L. Alexandrov, E. Ratner, M. Azodi, 2022, Gynecologic oncology.

The novel serine protease tumor‐associated differentially expressed gene–15 (matriptase/MT‐SP1) is highly overexpressed in cervical carcinoma

T. O'brien, S. Anfossi, L. E. De Las Casas, 2003, Cancer.

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

L. Alexandrov, A. Iwasaki, E. Ratner, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.

D. Katsaros, E. Diamandis, M. Marizzoni, 2006, American journal of obstetrics and gynecology.

Immunogenic gangliosides in human ovarian carcinoma.

T. S. Saravanan, D. Morton, S. Selvan, 2007, Biochemical and biophysical research communications.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2017, Clinical Cancer Research.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2014, Cancer medicine.

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

E. Ratner, D. Silasi, T. Rutherford, 2011, British Journal of Cancer.

Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.

S. Bellone, A. Santin, S. Pecorelli, 2003, Gynecologic oncology.

Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor

D. Silasi, P. Schwartz, T. Rutherford, 2011, Clinical & Experimental Metastasis.

Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.

S. Bellone, A. Santin, S. Pecorelli, 2003, Gynecologic oncology.

variant is a biomarker of poor outcome, platinum resistance and a potential target for therapy in ovarian cancer.

Linda, Trupti, F. Slack, 2016 .

Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer

G. Parham, P. Hermonat, S. Bellone, 2001, Gynecologic and Obstetric Investigation.

Induction of Ovarian Tumor‐Specific CD8+ Cytotoxic T Lymphocytes by Acid‐Eluted Peptide‐Pulsed Autologous Dendritic Cells

G. Parham, S. Bellone, A. Santin, 2000, Obstetrics and gynecology.

Restoration of Tumor-Specific HLA Class I Restricted Cytotoxicity in Tumor Infiltrating Lymphocytes of Advanced Breast Cancer Patients by in vitro Stimulation with Tumor Antigen-Pulsed Autologous Dendritic Cells

S. Bellone, A. Santin, M. Cannon, 2003, Breast Cancer Research and Treatment.

In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.

G. Parham, P. Hermonat, S. Bellone, 2000, American journal of obstetrics and gynecology.

Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer

T. O'brien, S. Bellone, A. Santin, 2004, BJOG : an international journal of obstetrics and gynaecology.

Restoration of tumor specific human leukocyte antigens class I‐restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer

S. Bellone, A. Santin, S. Pecorelli, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Increased levels of interleukin‐10 and transforming growth factor‐β in the plasma and ascitic fluid of patients with advanced ovarian cancer

G. Parham, S. Bellone, A. Santin, 2001 .

Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer.

C. V. Smith, G. Parham, S. Bellone, 2001, BJOG : an international journal of obstetrics and gynaecology.

Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy.

S. Bellone, A. Santin, S. Pecorelli, 2005, Current pharmaceutical design.

Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer.

G. Parham, S. Bellone, A. Santin, 2002, The New England journal of medicine.

Development and Therapeutic Effect of Adoptively Transferred T Cells Primed by Tumor Lysate-Pulsed Autologous Dendritic Cells in a Patient with Metastatic Endometrial Cancer

G. Parham, P. Hermonat, S. Bellone, 2000, Gynecologic and Obstetric Investigation.

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

P. Schwartz, D. Goldenberg, R. Sharkey, 2018, Gynecologic oncology reports.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

E. Ratner, D. Silasi, T. Rutherford, 2014, British Journal of Cancer.

HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.

P. Schwartz, T. Rutherford, E. Cocco, 2013, Gynecologic oncology.

Expression of &agr;V-Integrins in Uterine Serous Papillary Carcinomas; Implications for Targeted Therapy With Intetumumab (CNTO 95), a Fully Human Antagonist Anti-&agr;V-Integrin Antibody

P. Schwartz, T. Rutherford, P. Todeschini, 2011, International Journal of Gynecologic Cancer.

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.

L. Alexandrov, E. Ratner, M. Azodi, 2022, Gynecologic oncology.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

P. Schwartz, T. Rutherford, E. Cocco, 2014, Gynecologic oncology.

Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.

E. Sartori, P. Schwartz, T. Rutherford, 2012, Gynecologic oncology.

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

D. Silasi, P. Schwartz, T. Rutherford, 2013, American journal of obstetrics and gynecology.

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

E. Ratner, P. Schwartz, P. Hui, 2020, Gynecologic oncology reports.

Granulosa cell and oocyte mitochondrial abnormalities in a mouse model of fragile X primary ovarian insufficiency.

C. Giulivi, M. Ferrari, S. Bellone, 2016, Molecular human reproduction.

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.

E. Ratner, M. Azodi, P. Hui, 2022, Gynecologic oncology.

Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.

G. Parham, P. Hermonat, S. Bellone, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer

S. Bellone, A. Santin, S. Pecorelli, 2003, International Journal of Gynecologic Cancer.

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

P. Schwartz, S. Bellone, A. Santin, 2016, Gynecologic oncology reports.

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

P. Schwartz, L. Zammataro, S. Bellone, 2018, Gynecologic oncology reports.

Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.

G. Parham, P. Hermonat, S. Bellone, 2001, Gynecologic oncology.

Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial

E. Siegel, S. Bellone, A. Santin, 2007, Journal of Virology.

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.

S. Bellone, A. Santin, S. Pecorelli, 2006, Gynecologic oncology.

Advances in dendritic cell-based therapeutic vaccines for cervical cancer

S. Bellone, A. Santin, S. Pecorelli, 2007, Expert review of anticancer therapy.

HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas

R. Angioli, P. Schwartz, T. Rutherford, 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

S. Mane, T. Boggon, Kaya Bilgüvar, 2016, Proceedings of the National Academy of Sciences.

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Gloria S. Huang, G. Frampton, J. Newberg, 2019, Gynecologic oncology.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015, Molecular Cancer Therapeutics.

Dual HER 2 / PIK 3 CA Targeting Overcomes Single-Agent Acquired Resistance in HER 2-Ampli fi ed Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015 .

Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+ Cytotoxic T Lymphocytes

G. Parham, P. Hermonat, S. Bellone, 2000, Journal of virology.

Integrated mutational landscape analysis of uterine leiomyosarcomas

Gloria S. Huang, M. Imieliński, L. Alexandrov, 2021, Proceedings of the National Academy of Sciences.

Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.

L. Alexandrov, P. Dottino, E. Ratner, 2022, Gynecologic oncology.

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Gloria S. Huang, R. Lifton, J. Schlessinger, 2018, Proceedings of the National Academy of Sciences.

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pei Hui, Jonathan Black, David L Rimm, 2016, British Journal of Cancer.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines

F. Casagrande, D. Silasi, P. Schwartz, 2009, Journal of Virology.

Induction of human tumor‐associated differentially expressed gene‐12 (TADG‐12/TMPRSS3)‐specific cytotoxic T lymphocytes in human lymphocyte antigen‐A2.1–positive healthy donors and patients with advanced ovarian cancer

T. O'brien, S. Anfossi, D. Silasi, 2009, Cancer.

Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.

T. O'brien, S. Anfossi, D. Silasi, 2009, American journal of obstetrics and gynecology.

Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy.

Erming Tian, Alexander Burnett, Eric R Siegel, 2005, Virology.

A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer

F. Slack, J. Weidhaas, D. Katsaros, 2011, Oncogene.

Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.

Wang Min, Ge Lou, Ming-zhu Yin, 2016, The Journal of clinical investigation.

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

A. Secord, E. Ratner, L. Havrilesky, 2020, Clinical Cancer Research.

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

A. Secord, E. Ratner, L. Havrilesky, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

F. Casagrande, D. Silasi, T. Rutherford, 2009, British Journal of Cancer.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

E. Ratner, D. Silasi, T. Rutherford, 2012, British Journal of Cancer.

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

J. McKenney, S. Bellone, A. Santin, 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling

F. Zhan, J. Shaughnessy, E. Tian, 2004, British Journal of Cancer.

Overexpression of HER-2/neu in uterine serous papillary cancer.

G. Parham, T. O'brien, S. Bellone, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

R. Angioli, P. Schwartz, T. Rutherford, 2014, Gynecologic oncology.

Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin

F. Casagrande, P. Schwartz, T. Rutherford, 2011, Cancer.

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Gloria S. Huang, L. Alexandrov, A. Iwasaki, 2021, Cancer.

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement

D. Rimm, E. Ratner, P. Schwartz, 2018, Clinical Cancer Research.

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

T. Boggon, Murim Choi, Shrikant Mane, 2013, Proceedings of the National Academy of Sciences.

Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation

H. Taylor, X. Zhao, Y. Gao, 2014, Oncogene.

Influence of Allogeneic Blood Transfusion on Clinical Outcome during Radiotherapy for Cancer of the Uterine Cervix

G. Parham, S. Bellone, A. Santin, 2003, Gynecologic and Obstetric Investigation.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Gautam G. Rao, E. Ratner, D. Silasi, 2022, British Journal of Cancer.

Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.

Gloria S. Huang, E. Ratner, P. Schwartz, 2021, Gynecologic oncology.

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Gloria S. Huang, L. Alexandrov, T. Boggon, 2019, Proceedings of the National Academy of Sciences.

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

D. Silasi, P. Schwartz, T. Rutherford, 2010, American journal of obstetrics and gynecology.

Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy

D. Silasi, P. Schwartz, T. Rutherford, 2009, International Journal of Gynecologic Cancer.

Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy

F. Zhan, J. Shaughnessy, S. Bellone, 2005, British Journal of Cancer.

Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy

Erming Tian, F. Zhan, J. Shaughnessy, 2004, International journal of cancer.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody

F. Casagrande, D. Silasi, P. Schwartz, 2010, International Journal of Gynecologic Cancer.

Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.

J. McKenney, S. Bellone, A. Santin, 2008, American journal of obstetrics and gynecology.

Uterine serous papillary carcinomas overexpress human trophoblast‐cell‐surface marker (trop‐2) and are highly sensitive to immunotherapy with hRS7, a humanized anti‐trop‐2 monoclonal antibody

T. Rutherford, P. Todeschini, E. Cocco, 2011, Cancer.

Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

R. Lifton, J. Schlessinger, P. Schwartz, 2016, Clinical Cancer Research.

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

E. Ratner, D. Silasi, P. Schwartz, 2020, Frontiers in Oncology.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Scientific Reports.

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.

E. Ratner, M. Azodi, P. Hui, 2022, Gynecologic oncology.

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.

Gloria S. Huang, E. Ratner, D. Silasi, 2021, Gynecologic oncology.

The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.

P. Dottino, E. Ratner, M. Azodi, 2023, Gynecologic oncology.

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)

F. Casagrande, D. Silasi, P. Schwartz, 2010, Molecular Cancer Therapeutics.

Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Gloria S. Huang, E. Ratner, E. Siegel, 2021, Gynecologic Oncology.

Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis

A. Talhouk, S. Leung, D. Huntsman, 2021, Cancer.

Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.

P. Schwartz, T. Rutherford, E. Cocco, 2013, American journal of obstetrics and gynecology.

Overexpression of claudin‐3 and claudin‐4 receptors in uterine serous papillary carcinoma

M. Marizzoni, E. Siegel, S. Bellone, 2007, Cancer.

Distinct mechanisms of mismatch repair deficiency delineate two modes of response to PD-1 immunotherapy in endometrial carcinoma.

Ryan D. Chow, A. Iwasaki, E. Song, 2022, Cancer discovery.

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).

A. Jazaeri, M. Birrer, E. Ratner, 2020, Gynecologic oncology.

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

G. Krikun, F. Casagrande, D. Silasi, 2010, British Journal of Cancer.

Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.

S. Bellone, A. Santin, S. Pecorelli, 2007, Gynecologic oncology.

High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer.

S. Bellone, A. Santin, S. Pecorelli, 2005, Gynecologic oncology.

0348: Phase I Dose Escalation Trial of Hpv16/18 E7-Pulsed Dendritic Cell Vaccination in Stage Ib-Iia Cervical Cancer Patients

S. Bellone, A. Santin, S. Pecorelli, 2006, International Journal of Gynecologic Cancer.

Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs

C. Tuggle, M. Kiupel, J. Ross, 2019, Front. Oncol..

Serum amyloid A

T. Rutherford, E. Cocco, S. Bellone, 2010, Cancer.

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

E. Ratner, F. Casagrande, D. Silasi, 2009, British Journal of Cancer.

T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

S. Canevari, P. Schwartz, T. Rutherford, 2014, Clinical & Experimental Metastasis.

Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer

G. Mor, F. Casagrande, Han-Hsuan Fu, 2010, BMC Cancer.

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.

J. Schlessinger, E. Ratner, G. Bollag, 2023, Gynecologic oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

N. Rothman, Q. Lan, E. Ratner, 2015, British Journal of Cancer.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

E. Ratner, D. Silasi, M. Azodi, 2019, Scientific Reports.

Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.

E. Tian, L. E. De Las Casas, S. Bellone, 2005, Gynecologic oncology.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

E. Sartori, E. Ratner, D. Silasi, 2017, Gynecologic oncology.

Improved survival of patients with hypermutation in uterine serous carcinoma

R. Lifton, J. Schlessinger, S. Bellone, 2015, Gynecologic oncology reports.

A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells

M. Nakagawa, S. Bellone, A. Santin, 2009, Cancer Immunology, Immunotherapy.

Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)

M. Birrer, E. Ratner, H. Lankes, 2020, Gynecologic oncology reports.

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Gloria S. Huang, E. Ratner, Serena Wong, 2017, Gynecologic oncology.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Gynecologic oncology.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

Gloria S. Huang, J. Schlessinger, E. Ratner, 2018, Clinical Cancer Research.

Amplification of c‐erbB2 oncogene

E. Siegel, L. E. De Las Casas, S. Bellone, 2005, Cancer.

In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Gloria S. Huang, E. Ratner, Serena Wong, 2018, Molecular Cancer Therapeutics.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

E. Ratner, W. Saltzman, D. Silasi, 2016, Molecular Cancer Therapeutics.

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody

Paola Todeschini, Masoud Azodi, Marta Betti, 2011, Journal of experimental & clinical cancer research : CR.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2017, Medical Oncology.

Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones

E. Ratner, D. Silasi, T. Rutherford, 2013, Cancer.

Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer

C. Zeiss, E. Ratner, W. Saltzman, 2015, International journal of cancer.

Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.

E. Siegel, F. Casagrande, P. Schwartz, 2010, Gynecologic oncology.

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy

S. Bellone, A. Santin, B. McNamara, 2023, Gynecologic oncology reports.

Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone.

M. Nakagawa, S. Bellone, A. Santin, 2006, Cancer immunity.

Vessel-Targeting Nanoclovers Enable Noninvasive Delivery of Magnetic Hyperthermia-Chemotherapy Combination for Brain Cancer Treatment.

A. Chen, Jiangbing Zhou, Fuyao Liu, 2021, Nano letters.

Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.

E. Siegel, S. Bellone, A. Santin, 2005, Cancer research.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

E. Ratner, D. Silasi, P. Schwartz, 2016, American journal of obstetrics and gynecology.

Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers

E. Siegel, S. Bellone, A. Santin, 2023, International journal of molecular sciences.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Gynecologic oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

E. Siegel, E. Ratner, D. Silasi, 2013, British Journal of Cancer.

Supplementary Table 4a

E. Siegel, E. Ratner, D. Silasi, 2013 .

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression.

E. Sartori, P. Schwartz, T. Rutherford, 2012, Gynecologic oncology.

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation.

D. DiMaio, S. Bellone, A. Santin, 2012, Virology.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Gloria S. Huang, Abhijit A. Patel, D. Levine, 2018, Gynecologic oncology.

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.

E. Ratner, M. Azodi, B. Paolini, 2024, Proceedings of the National Academy of Sciences of the United States of America.

Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]

M. Birrer, E. Ratner, H. Lankes, 2020, Gynecologic oncology reports.

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.